LONDON--(BUSINESS WIRE)--Sep 11, 2018--Technavio has announced their latest . The report includes a comprehensive research on the pipeline molecules under investigation by the pharmaceutical companies within the defined data collection period for the treatment of dengue. The report also includes a study of the pipeline molecules in various stages including, on-going clinical trials, discovery, and pre-clinical.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180911005771/en/
Technavio has published a new report on the drug development pipeline for the treatment of dengue, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
Dengue: An overview
Dengue is a mosquito-borne tropical disease caused by the dengue virus which is typically a single positive-stranded RNA virus. Dengue is transmitted through the bite of infected Aedes mosquito, mainly Aedes aegypti and Aedes albopictus. Dengue occurs when the virus remains in the bloodstream for seven days, which in turn, infects the blood of the person. Therefore, dengue can be transmitted through exposure to infected blood, organs, or other tissues.
Dengue is prevalent in tropics and sub-tropics, owing to the optimal rainfall in these regions, which creates a prominent environment for the breeding of Aedes mosquitoes. Dengue occurs majorly in 100 countries of Asia, the Pacific, the Americas, Africa, and the Caribbean. According to CDC in June 2014, the WHO estimated that 50 to 100 million infections occur yearly, which comprises of 500,000 DHF cases and 22,000 deaths, mostly among children. Most cases of dengue were reported in 48 continental states where most of the travelers and immigrants are found.
Dengue: Segmentation of pipeline molecules
Technavio’s research segments the pipeline molecules based on different phases of drug development including, therapies employed, route of administration (RoA), mechanism of action (MoA), therapeutic modality, and the targets for the drugs under development. In the current drug pipeline, the most preferred MoA remains immunostimulant, with around 56% of the pipeline molecules administered through this mode.
Between companies and institutions collaborate for utilizing the technology properly, which is required for further development and commercialization of molecules. In the current pipeline, company+institution led the drug development space for the treatment of dengue. Some of the key players include ABIVAX, BioNet-Asia, Codagenix, and GlaxoSmithKline.
Some of the key topics covered in the report include:
1.Scope of the Report
3.Drug Development Landscape
Drugs under development
4.Drug Development Strategies
Therapies employedRoute of administrationTherapeutic modalityMechanism of action
Geographical coverageRecruitment statusGenderAge
Type of playersCompany overview
7.Discontinued and Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180911005771/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: TECHNOLOGY OTHER TECHNOLOGY HEALTH INFECTIOUS DISEASES RESEARCH OTHER SCIENCE SCIENCE GENERAL HEALTH
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 09/11/2018 03:15 PM/DISC: 09/11/2018 03:15 PM